Novo Nordisk's GLP‑1 RA--A Modern Treatment for Obesity Management--is Linked to Lower Household Spending on Alcohol and Tobacco
Real-world data analysis suggests that families with at least one member using Novo Nordisk's GLP‑1 RA for weight management tend to reduce spending on alcohol and cigarettes. JAKARTA, Indonesia, Jan. 12, 2026 /PRNewswire/ -- At the international...
Novo Nordisk International Operations Commits to Veeva Vault CRM
Chooses industry leading Vault CRM to empower commercial teams with next-generation CRM capabilities and agentic AI SINGAPORE, Jan. 8, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Novo Nordisk's International Operations...
Veeva AI Agents Now Available to Increase Productivity and Customer Centricity
Veeva AI delivers industry-specific AI for the next chapter in life sciences SINGAPORE, Dec. 4, 2025 /PRNewswire/ -- In a major milestone for Veeva AI, industry-specific AI for life sciences, Veeva Systems (NYSE: VEEV) today announced the...
Hedia appoints new CEO: Rasmus Kofoed to succeed Lars Christian Lund
COPENHAGEN, Denmark, Dec. 1, 2025 /PRNewswire/ -- Danish diabetes‑tech company Hedia is implementing a leadership change effective 1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund,...
Alzheimer's Association Statement on Oral Semaglutide Phase 3 Topline Data Release
- Results Underscore Need for Continued Research and Diverse Treatment Pipeline CHICAGO, Nov. 24, 2025 /PRNewswire/ -- The Alzheimer's Association is disappointed that the evoke and evoke+ clinical trials did not demonstrate a statistically...
Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management
Wegovy® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in...
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and...
Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report
Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced...